. . . . "http://www.isvav.cz/projectDetail.do?rowId=IAA400040803"^^ . . "The results obtained within this project extend theoretical background on the mechanism of antitumor effects of photoactivatable transition metal-based compounds. The results made it possible to design new compounds for photodynamic therapy."@en . . . "20"^^ . . "Mechanistic studies related to targeted cancer chemotherapy with light-activated platinum and ruthenium antitumor agents"@en . "20"^^ . "cancer chemotherapy; photoactivatable metallodrugs; DNA damage; photodynamic therapy; platinum; ruthenium; cisplatin"@en . "2011-03-18+01:00"^^ . . . "0"^^ . "cancer chemotherapy" . " photoactivatable metallodrugs" . "2008-01-01+01:00"^^ . "1"^^ . . " platinum" . "2013-06-28+02:00"^^ . "0"^^ . . . . " DNA damage" . " ruthenium" . "2011-12-31+01:00"^^ . " photodynamic therapy" . . . . . "Hlavn\u00EDm c\u00EDlem projektu je roz\u0161\u00ED\u0159it znalosti o mechanismu p\u016Fsoben\u00ED sv\u011Btlocitliv\u00FDch protin\u00E1dorov\u011B \u00FA\u010Dinn\u00FDch slou\u010Denin kov\u016F a vyu\u017E\u00EDt takto z\u00EDskan\u00FDch znalost\u00ED k v\u00FDvoji nov\u00FDch t\u0159\u00EDd metalofarmak se zcela nov\u00FDm mechanismem p\u016Fsoben\u00ED a spektrem biologick\u00E9 \u00FA\u010Dinnosti. Budou navr\u017Eeny a studov\u00E1ny sv\u011Btlem aktivovateln\u00E9 komplexy p\u0159echodn\u00FDch kov\u016F, schopn\u00E9 p\u0159ekonat nev\u00FDhody spojen\u00E9 s klinickou aplikac\u00ED konven\u010Dn\u00EDho cytostatika cisplatiny a jej\u00EDch analog (rezistence, omezen\u00E9 spektrum protin\u00E1dorov\u00E9 aktivity, n\u00EDzk\u00E1 specificita, vedlej\u0161\u00ED \u00FA\u010Dinky) d\u00EDky odli\u0161n\u00E9mu p\u016Fsoben\u00ED na molekul\u00E1rn\u00ED \u00FArovni, a takto z\u00EDskan\u00E9 poznatky budou vyu\u017Eity k racionalizaci procesu navrhov\u00E1n\u00ED nov\u00FDch metalofarmak. Hlavn\u00ED o\u010Dek\u00E1van\u00E9 v\u00FDsledky: budou navr\u017Eeny nov\u00E9, sv\u011Btlem aktivovateln\u00E9 komplexy kov\u016F v\u010Detn\u011B vytvo\u0159en\u00ED teoretick\u00E9ho z\u00E1zem\u00ED zahrnuj\u00EDc\u00ED biochemick\u00E9, molekul\u00E1rn\u011B biologick\u00E9 a farmakologick\u00E9 aspekty p\u016Fsoben\u00ED t\u011Bchto komplex\u016F s c\u00EDlem navrhnout nov\u00E9 a \u00FA\u010Dinn\u011Bj\u0161\u00ED kandid\u00E1ty l\u00E9\u010Div pro klinick\u00E9 zkou\u0161ky." . . . "The main objective is to increase knowledge and understanding of the design and mechanisms of action of photoactivatable antitumour metallodrugs, and to use this enhanced knowledge to develop new classes of metallodrugs with truly novel mechanisms of action and novel spectra of biomedical activity. Secondary objectives are to design and study photoactivatable transition metal-based agents that circumvent known clinical drawbacks of %22conventional%22 antitumor cisplatin and its analogs (resistance, limited spectrum of activity, lack of specificity, side-effects) through different molecular-level actions and use this knowledge to underpin the process of designing new metallodrugs. Major outcome expected: new photoactivatable metallodrugs will be proposed and the associated biochemistry, molecular biology and pharmacology will be developed and examined to bring novel and more effective drug candidates to clinical trials."@en . "Mechanistick\u00E9 studie maj\u00EDc\u00ED vztah k c\u00EDlen\u00E9 chemoterapii rakoviny pomoc\u00ED komplex\u016F platiny a ruthenia aktivovateln\u00FDch sv\u011Btlem" . "IAA400040803" . "V\u00FDsledky dosa\u017Een\u00E9 v r\u00E1mci tohoto projektu roz\u0161\u00ED\u0159ily teoretick\u00E9 znalosti o mechanismu protin\u00E1dorov\u00FDch \u00FA\u010Dink\u016F sv\u011Btlem aktivovateln\u00FDch slou\u010Denin p\u0159echodn\u00FDch kov\u016F. V\u00FDsledky tak\u00E9 umo\u017Enily navrhnout nov\u00E9 slou\u010Deniny jako kandid\u00E1ty pro fotodynamickou terapii."@cs .